We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BioCryst Yanks IND on Hep Drug After FDA Safety Concerns
BioCryst Yanks IND on Hep Drug After FDA Safety Concerns
November 2, 2012
BioCryst Pharmaceuticals has decided to pull its IND for a new hepatitis C (HCV) drug after the FDA raised concerns about the drug’s toxicity profile.